- Home
- AIFF vs NRXS Comparison
AIFF vs NRXS Comparison
Compare AIFF & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- NRXS
- Stock Information
- Founded
- AIFF 2006
- NRXS 2011
- Country
- AIFF Canada
- NRXS United States
- Employees
- AIFF N/A
- NRXS N/A
- Industry
- AIFF
- NRXS
- Sector
- AIFF
- NRXS
- Exchange
- AIFF NYSE
- NRXS Nasdaq
- Market Cap
- AIFF 24.9M
- NRXS 20.3M
- IPO Year
- AIFF N/A
- NRXS 2023
- Fundamental
- Price
- AIFF $2.93
- NRXS $3.13
- Analyst Decision
- AIFF
- NRXS
- Analyst Count
- AIFF 0
- NRXS 0
- Target Price
- AIFF N/A
- NRXS N/A
- AVG Volume (30 Days)
- AIFF 65.7K
- NRXS 25.3K
- Earning Date
- AIFF 11-14-2024
- NRXS 11-12-2024
- Dividend Yield
- AIFF N/A
- NRXS N/A
- EPS Growth
- AIFF N/A
- NRXS N/A
- EPS
- AIFF N/A
- NRXS N/A
- Revenue
- AIFF $74,000.00
- NRXS $2,456,219.00
- Revenue This Year
- AIFF N/A
- NRXS $383.16
- Revenue Next Year
- AIFF N/A
- NRXS N/A
- P/E Ratio
- AIFF N/A
- NRXS N/A
- Revenue Growth
- AIFF N/A
- NRXS N/A
- 52 Week Low
- AIFF $2.74
- NRXS $2.00
- 52 Week High
- AIFF $15.90
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- AIFF 42.66
- NRXS 56.84
- Support Level
- AIFF $2.92
- NRXS $3.03
- Resistance Level
- AIFF $3.36
- NRXS $3.31
- Average True Range (ATR)
- AIFF 0.34
- NRXS 0.40
- MACD
- AIFF -0.02
- NRXS 0.06
- Stochastic Oscillator
- AIFF 9.52
- NRXS 60.57
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).